Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment.

          Related collections

          Author and article information

          Journal
          J Thorac Oncol
          Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
          Elsevier BV
          1556-1380
          1556-0864
          Apr 2017
          : 12
          : 4
          Affiliations
          [1 ] National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Liverpool Hospital, Sydney, Australia.
          [2 ] National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; School of Medicine, The University of Notre Dame, Sydney, Australia.
          [3 ] National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia.
          [4 ] Cancer Care Centre, St. George Hospital, Sydney, Australia.
          [5 ] Department of Medical Oncology, Liverpool Hospital, Sydney, Australia.
          [6 ] Albert Einstein College of Medicine, Jacobi Medical Center, New York, New York.
          [7 ] Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Republic of China.
          [8 ] National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; Cancer Care Centre, St. George Hospital, Sydney, Australia. Electronic address: chee.lee@ctc.usyd.edu.au.
          Article
          S1556-0864(16)33582-1
          10.1016/j.jtho.2016.11.2236
          28007626

          Comments

          Comment on this article